

sFTX-3.3 biochemical

sFTX-3.3

CATALOG #
AAA227669


PRODUCT SYNONYMS

sFTX-3.3; sFTX-3.3 biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	141997-14-0
Targets&IC50	P-type calcium channel:0.24 mM (IC50), N-Type Ca ²⁺ Channel:0.70 mM (IC50)
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	sFTX-3.3 (100 uM) reduces the duration of the slow component of presynaptic calcium currents by about 50% of the control and also reduces presynaptic sodium current by approximately 20% of the control. sFTX-3.3 (100 uM) reduces whole-cell sodium current recorded from SK.N.SH cells by approximately 15%[3].
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
Lopinavir Metabolite M-1, CAS 192725-39-6



Structure
Lopinavir Metabolite M-1, CAS 192725-39-6

ADDITIONAL INFORMATION

Related Product Information for sFTX-3.3 biochemical	sFTX-3.3 is a Ca ²⁺ channel antagonist with IC ₅₀ s of approximately 0.24 mM and 0.70 mM against P-type and N-type channels.
References	- Sham HL, et, al. Synthesis and antiviral activities of the major metabolites of the HIV protease inhibitor ABT-378 (Lopinavir). Bioorg Med Chem Lett. 2001 Jun 4; 11(11): 1351-3. - Kumar GN, et, al. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction. Drug Metab Dispos. 1999 Aug; 27(8): 902-8.

NCBI AND UNIPROT INFORMATION

Molecular Weight	642.797
------------------	---------

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | contact@aaabiotech.com
Online datasheet: <https://www.aaabiotech.com/biochemical/sftx-3-3/227669>